-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Androgen-affected (AR) signaling pathlands drive tumor growth in prostate cancer and treat drug resistance.
advanced or metastatic prostate cancer (PCa) is mainly focused on androgen deprivation therapy (ADT).
although ADT generally causes the disease to subside, most prostate cancers become resistant due to changes in the androgen-borne (AR) signaling pathline.
cancer, also known as hyperly resistant prostate cancer (CRPC), is still progressing after the initial acceptance of ADT.
docetaxel is a standard first-line chemotherapy drug, and recent clinical studies have showed that the combination of docetaxel and ADT can be effective in improving the prognostic prognostics of hormone-sensitive diseases.
testosterone supplementation can seriously impair the accumulation and efficacy of dorcamine The study aims to explore whether testosterone and AR signals interfere with the efficacy of dorcestion in the treatment of CRPC.
researchers found that in the CRPC model, testosterone supplementation significantly affected the accumulation of dossythase in tumors, thereby reducing the stability of micro-tube proteins and anti-tumor effects.
testosterone and AR signal activity interfere with the anti-tumor effects of dossythase, testosterone can compete with dossythase for the intake of the drug transporter protein OATP1B3.
regardless of the stability of the micro-tube protein caused by Dorsey, testosterone-induced AR signaling paths can counteract the therapeutic effect of Dorsey.
the activation of ar signaling paths can also reverse the long-term tumor receding effects caused by dossytherapy.
results suggest that to optimize the therapeutic effect of dossythase, it is necessary to inhibit androgen levels and the activity of the AR signal transducting path.
, the study revealed that in hyperactive prostate cancer, the continued activity of androgen-like signals maximizes the inhibition of the effects of targeted therapy drugs in combined therapy with dositase.
.